- Home
- FIGX vs SGMT Comparison
FIGX vs SGMT Comparison
Compare FIGX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FIGX | SGMT |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 164.6M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FIGX | SGMT |
|---|---|---|
| Price | $10.10 | $5.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 51.8K | ★ 827.1K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $125.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $1.73 |
| 52 Week High | $10.15 | $11.41 |
Technical Indicators
Market Signals| Indicator | FIGX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 37.97 |
| Support Level | $10.10 | $5.04 |
| Resistance Level | $10.15 | $5.74 |
| Average True Range (ATR) | 0.02 | 0.49 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 9.09 | 4.35 |
Price Performance
Historical ComparisonAbout FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share
FIGX Capital Acquisition Corp is a blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.